Amgen Ltd

240 Cambridge Science Park, Milton Road, Cambridge, CB4 0WD
Telephone: +44 (0)1223 420 305
Fax: +44 (0)1223 426 314
Medical Information Direct Line: +44 (0)1223 436 441
Medical Information e-mail: gbinfoline@amgen.com
Customer Care direct line: +44 (0)808 0100 321
Medical Information Fax: +44 (0)1223 426 314
Summary of Product Characteristics last updated on the eMC: 11/02/2010
SPC NEULASTA

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 11/02/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   23-Oct-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

New clinical data from a study in paediatric patients has led to the revision of the sections on Undesirable effects (section 4.8), pharmacodynamics (section 5.1) and pharmacokinetis (section 5.2).
Section 6.5 updated to include new presentation with automatic needle guard.
Updated on 17/07/2008 and displayed until 11/02/2010
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.2 - Pharmacokinetic Properties
Date of revision of text on the SPC:   21-Apr-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.2 information relating to renal impairment - no dose change recommended
Section 4.8 very rare undesirable effects added
Section 5.2 open label data added re renal impairment and PK of pegfilgrastim
Updated on 05/11/2007 and displayed until 17/07/2008
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 31/08/2007 and displayed until 05/11/2007
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 28/02/2007 and displayed until 31/08/2007
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 23/02/2007 and displayed until 28/02/2007
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6. 5 - Nature and Contents of Container
Date of revision of text on the SPC:   01/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.4 - Special warnings and precautions for use
Addition of text re sickle cell crises.

Addition of text re the needle cover containing dry natural rubber which may cause allergic reactions.

Addition of text re bone imaging findings.

Section 4.8 Undesirable effects

Addition of text re rare events of cutaneous vasculitis and isolated cases of sickle cell crises.

Section 6.5 Nature and contents of container

Addition of needle cover containing dry natural rubber

Updated on 21/07/2006 and displayed until 23/02/2007
Reasons for adding or updating:
  • Removal of Black Triangle
Date of revision of text on the SPC:   10/2005
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

 
Removal of Black Triangle
 
Updated on 21/07/2006 and displayed until 21/07/2006
Reasons for adding or updating:
  • Removal of Black Triangle
Date of revision of text on the SPC:   10/2005
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company


Removal of Black Triangle.
Updated on 22/11/2005 and displayed until 21/07/2006
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
Updated on 12/08/2004 and displayed until 22/11/2005
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 09/08/2004 and displayed until 12/08/2004
Reasons for adding or updating:
  • Change to section 6. 3 - Shelf Life
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 10 (date of (partial) revision of the text
Updated on 05/03/2004 and displayed until 09/08/2004
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Updated on 04/03/2004 and displayed until 05/03/2004
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
  • Pending awaiting re-submission
Updated on 31/03/2003 and displayed until 04/03/2004
Reasons for adding or updating:
  • New SPC for new product

Active Ingredients/Generics

 
   pegfilgrastim


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk